Cardio Diagnostics Advances Cardiovascular Disease Detection with AI-Powered Epigenetic Testing Platform

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) has developed a proprietary platform that integrates epigenetic and genetic biomarkers with artificial intelligence to generate personalized cardiovascular insights from a simple blood sample. Cardiovascular disease remains the leading cause of death in the United States, representing a significant and persistent healthcare burden that the company's solutions are designed to address. The company's clinical tests are non-invasive, require no fasting or radiation, and are designed to detect and assess coronary heart disease, including forms that may not be identified through traditional diagnostic methods.

Recent developments include expanded provider partnerships across the United States, finalized CMS reimbursement rates of $854 for its clinical tests, initial international expansion into India, and clinical data presentations supporting its ability to detect forms of coronary heart disease that traditional tools may miss. The company has established multiple commercialization channels, including provider networks, employer partnerships, and community-based programs, to expand access to its cardiovascular testing solutions. Cardio Diagnostics Holdings is an artificial intelligence-powered precision cardiovascular medicine company focused on making cardiovascular disease prevention, detection, and management more accessible, personalized, and precise.

The company's approach is centered on advancing how cardiovascular disease is addressed by moving beyond traditional methods that rely on indirect or generalized indicators. At the core of its strategy is the integration of epigenetics, genetics, and artificial intelligence to generate insights from a patient's molecular profile. By analyzing both inherited predisposition and changes influenced by lifestyle and environment, the company's platform is designed to provide a more comprehensive assessment of cardiovascular risk. This matters because cardiovascular disease continues to be the leading cause of mortality in the United States, and current diagnostic methods often fail to detect certain forms of coronary heart disease until they become advanced.

The implications of this announcement are significant for both healthcare providers and patients. The establishment of CMS reimbursement at https://www.cms.gov creates a pathway for broader insurance coverage and adoption of these advanced diagnostic tools. The international expansion into markets like India represents potential for addressing cardiovascular disease burden in diverse populations. The company's focus on epigenetic biomarkers represents a shift toward more personalized medicine approaches that consider both genetic predisposition and environmental influences on disease development. This approach could lead to earlier detection and more targeted interventions for cardiovascular conditions that traditional diagnostic methods might miss.

The company's news and updates are available in its newsroom at https://ibn.fm/CDIO. The development of this technology matters because it addresses a critical gap in cardiovascular disease detection and management. Traditional diagnostic methods often rely on indirect indicators or become effective only after significant disease progression has occurred. By combining epigenetic analysis with artificial intelligence, Cardio Diagnostics aims to provide earlier, more accurate detection that could enable preventive interventions before serious cardiovascular events occur. The company's multi-channel commercialization strategy suggests a commitment to making this technology accessible across different healthcare settings and patient populations.